Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood-Brain Barrier Clear all
Recruiting Phase 3 Interventional

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

NCT05317858
View directory record Official record
Conditions
Brain Tumor, Non Small Cell Lung Cancer
Interventions
Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab, Iptilimumab
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Newport Beach, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 10:27 AM EDT
Suspended Phase 1 Interventional

Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT04222309
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer
Interventions
Laparoscopically harvested omental free flap
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 26, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jun 26, 2026, 10:27 AM EDT
Terminated No phase listed Observational

(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas

NCT01281982
View directory record Official record
Conditions
Low Grade Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Oligoastrocytoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

NCT02819479
View directory record Official record
Conditions
Radiation Necrosis
Interventions
25% Mannitol, Low-dose Intra-arterial Bevacizumab
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jun 26, 2026, 10:27 AM EDT
Withdrawn Phase 2 Interventional

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

NCT05879120
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab
Drug · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 26, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

NCT03727841
View directory record Official record
Conditions
Anaplastic Ependymoma, Ependymoma, Ependymomas
Interventions
Marizomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jun 26, 2026, 10:27 AM EDT
Not listed Phase 1Phase 2 Interventional

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

NCT00983398
View directory record Official record
Conditions
Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma, Medulloepithelioma, Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Germ Cell Tumor, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
Interventions
Carboplatin, Mannitol, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Health Evaluation in African Americans Using RAS Therapy

NCT02471833
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Telmisartan 20mg, Telmisartan 40mg, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jun 26, 2026, 10:27 AM EDT
Recruiting Phase 3 Interventional

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

NCT05902169
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
Device · Drug
Lead sponsor
CarThera
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 26, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

NCT00001502
View directory record Official record
Conditions
Brain Neoplasms, Glioma, Medulloblastoma
Interventions
RMP-7 and carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

NCT04876638
View directory record Official record
Conditions
Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect
Interventions
Minocyclin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Early Phase 1 Interventional Results available

Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration

NCT02389738
View directory record Official record
Conditions
Blood Brain Barrier Defect
Interventions
Regadenoson, Temozolomide, Microdialysis catheter
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jun 26, 2026, 10:27 AM EDT
Completed No phase listed Observational Results available

MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy

NCT02031237
View directory record Official record
Conditions
Brain Metastases
Interventions
Single Fraction Stereotactic Radiosurgery (SRS), Fractionated Whole Brain Radiation Therapy (WBRT), Fractionated Stereotactic Radiation Therapy (FSRT), Magnetic Resonance Imaging (MRI) Assessments
Radiation · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jun 26, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline

NCT05556395
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jun 26, 2026, 10:27 AM EDT
Recruiting Early Phase 1 Interventional

Type 2 Diabetes and Blood Brain Barrier Improvement

NCT06322212
View directory record Official record
Conditions
Type2diabetes
Interventions
Thiamine, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Phase 2 Interventional

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

NCT01480583
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
GRN1005, Trastuzumab, 18F-FLT
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Harvey, Illinois • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 26, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT05979064
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer, High Grade Glioma
Interventions
Laparoscopically harvested omental tissue autograft
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 26, 2026, 10:27 AM EDT
Enrolling by invitation No phase listed Observational

Blood-Brain Barrier Integrity and Immune Dynamics in Neuropsychiatric Sequelae of Post-SARS-CoV-2 Onset ME/CFS Versus Pre-Pandemic ME/CFS Patients

NCT07256795
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 26, 2026, 10:27 AM EDT
Enrolling by invitation Not applicable Interventional

The Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier

NCT04063514
View directory record Official record
Conditions
Low Grade Glioma of Brain
Interventions
Focused Ultrasound
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

NCT00303849
View directory record Official record
Conditions
Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma
Interventions
Carboplatin, Etoposide, Etoposide Phosphate, Laboratory Biomarker Analysis, Mannitol, Melphalan, Quality-of-Life Assessment, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jun 26, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT03996447
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Panorama City, California • Farmington, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 26, 2026, 10:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers as Predictors of Suicidal Risk in Adolescents

NCT03014518
View directory record Official record
Conditions
Suicide, Attempted, Suicidal Ideation, Suicidal Intention, Suicide
Interventions
Clinical assessments and blood samples; follow-up for 12 mos, Clinical assessments and blood samples; no 12mo follow-up
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 26, 2026, 10:27 AM EDT